4 insiders at AbCellera Biologics Inc. (ABCL) reported open-market stock purchases totaling $1,917,492 in recent weeks, according to filings with the U.S. Securities and Exchange Commission. The largest reported purchase came from Hayden Michael R (director), who acquired 53,613 shares at $10.64 on August 24, 2026.
Source: SEC Form 4. Option grants and tax-withholding sales are excluded.
| Date | Insider | Role | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|
| 2026-08-24 | Hayden Michael R | director | 53,613 | $10.64 | $570,442 | SEC Form 4 |
| 2026-08-18 | Montalbano John S. | director | 10,000 | $11.03 | $110,300 | SEC Form 4 |
| 2026-08-14 | Booth Andrew | officer: Chief Financial Officer | 37,200 | $10.32 | $383,904 | SEC Form 4 |
| 2026-08-12 | Hayden Michael R | director | 46,387 | $10.37 | $481,033 | SEC Form 4 |
| 2026-05-14 | Montalbano John S. | director | 20,000 | $4.77 | $95,400 | SEC Form 4 |
| 2026-02-27 | Thermopylae Holdings Ltd. | 10 percent owner | 38,000 | $3.44 | $130,720 | SEC Form 4 |
| 2026-02-27 | Booth Andrew | officer: Chief Financial Officer | 42,600 | $3.42 | $145,692 | SEC Form 4 |
AbCellera Biologics Inc. is a Healthcare company in the Biotechnology industry. It carried a market capitalization of about $3.2B, with shares trading near $10.61.
This article is automated factual reporting of public SEC filings, for informational purposes only. It is not investment advice, nor a recommendation, offer or solicitation to buy or sell any security, and reflects no opinion on the company. Figures are drawn from filings believed reliable but are not guaranteed. Always verify against the primary SEC filing and consult a licensed professional. Investing can lose value, up to total loss.